180 Jaksot

  1. Adjuvant Therapy for Stage II Colon Cancer Guideline Update

    Julkaistiin: 22.12.2021
  2. Management of Stage III NSCLC Guideline

    Julkaistiin: 22.12.2021
  3. Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline

    Julkaistiin: 21.12.2021
  4. Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline

    Julkaistiin: 13.12.2021
  5. Abemaciclib with Endocrine Therapy in the Treatment of High-Risk Early Breast Cancer: ASCO Optimal Adjuvant Chemotherapy and Targeted Therapy Guideline Rapid Recommendation Update

    Julkaistiin: 10.12.2021
  6. Considerations for the Use of Steroids: Management of irAEs Guideline (Part 13)

    Julkaistiin: 16.11.2021
  7. Ocular Toxicities: Management of irAEs Guideline (Part 12)

    Julkaistiin: 15.11.2021
  8. Cardiovascular Toxicities: Management of irAEs Guideline (Part 11)

    Julkaistiin: 12.11.2021
  9. Hematologic Toxicities: Management of irAEs Guideline (Part 10)

    Julkaistiin: 11.11.2021
  10. Nervous System Toxicities: Management of irAEs Guideline (Part 9)

    Julkaistiin: 10.11.2021
  11. Renal Toxicities: Management of irAEs Guideline (Part 8)

    Julkaistiin: 9.11.2021
  12. Musculoskeletal Toxicities: Management of irAEs Guideline (Part 7)

    Julkaistiin: 8.11.2021
  13. Endocrine Toxicities: Management of irAEs Guideline (Part 6)

    Julkaistiin: 5.11.2021
  14. Lung Toxicities: Management of irAEs Guideline (Part 5)

    Julkaistiin: 4.11.2021
  15. Gastrointestinal Toxicities: Management of irAEs Guideline (Part 4)

    Julkaistiin: 3.11.2021
  16. Cutaneous Toxicities: Management of irAEs Guideline (Part 3)

    Julkaistiin: 2.11.2021
  17. ICPi Overview: Management of irAEs Guideline (Part 1)

    Julkaistiin: 1.11.2021
  18. CAR-T Cell Therapy: Management of irAEs Guideline (Part 2)

    Julkaistiin: 1.11.2021
  19. Immunotherapy in Patients with Locally Advanced Esophageal Carcinoma: ASCO Guideline Rapid Recommendation Update

    Julkaistiin: 18.8.2021
  20. Adjuvant PARP Inhibitors in Patients with High-risk Early-Stage HER2-Negative Breast Cancer and Germline BRCA Mutations: ASCO Hereditary Breast Cancer Guideline Rapid Recommendation Update

    Julkaistiin: 3.8.2021

5 / 9

Explore pivotal recommendations from the latest evidence-based clinical practice guidance with ASCO Guidelines. Join us to discover essential insights and navigate the ever-evolving landscape of cancer research and treatment.

Visit the podcast's native language site